Epidemiology of Sepsis in Turkish ICUs.

Epidemiology of Sepsis in Turkish ICUs :a National Point Prevalence Multi-centre Study.

The prevalence and mortality of sepsis in Turkey is not know at large. Turkish Society of Intensive Care Medicine, Sepsis Study Group conducted a multi-centre,point prevalence survey to determine the prevalence, causative micro-organisms and outcome of sepsis in Turkish ICUs.

Study Overview

• Status: Completed
• Conditions: Sepsis; Septic Shock; Severe Sepsis
• Intervention / Treatment: Other: No intervention

• Study Type: Observational
• Enrollment (Actual): 1499

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

All patients (>18 yr)present on the participating ICU or admitted to participating ICUs on study day

Description

Inclusion Criteria:All patients present on or admitted to participating ICU on study day.

Exclusion Criteria:

• Age<18 years
• Patients who underwent cardiovascular surgery.

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Infection only; The patients have only infection	Other: No intervention
Infection + SIRS; Patients have infection plus systemic inflammatory response syndrome (SIRS)	Other: No intervention
Severe sepsis; Septic patients with newly developed organ dysfunctions	Other: No intervention
Septic shock; Sepsis plus sepsis related hypotension	Other: No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of sepsis	The prevalence of sepsis,Severe sepsis and septic shock on study day	Up to 12 weeks.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mortality rate of sepsis	Mortality rate of septic shock	Mortality at 30 days

Collaborators and Investigators

• Sponsor: Nur Baykara
• Collaborators: Turkish Society of Intensive Care, Sepsis Study Group

Publications and helpful links

General Publications

• Rhodes A, Phillips G, Beale R, Cecconi M, Chiche JD, De Backer D, Divatia J, Du B, Evans L, Ferrer R, Girardis M, Koulenti D, Machado F, Simpson SQ, Tan CC, Wittebole X, Levy M. The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study). Intensive Care Med. 2015 Sep;41(9):1620-8. doi: 10.1007/s00134-015-3906-y. Epub 2015 Jun 25.
• Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, Angus DC, Reinhart K; International Forum of Acute Care Trialists. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir Crit Care Med. 2016 Feb 1;193(3):259-72. doi: 10.1164/rccm.201504-0781OC.
• Falagas ME, Rafailidis PI, Kofteridis D, Virtzili S, Chelvatzoglou FC, Papaioannou V, Maraki S, Samonis G, Michalopoulos A. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother. 2007 Nov;60(5):1124-30. doi: 10.1093/jac/dkm356. Epub 2007 Sep 20.
• Baykara N, Akalin H, Arslantas MK, Hanci V, Caglayan C, Kahveci F, Demirag K, Baydemir C, Unal N; Sepsis Study Group. Epidemiology of sepsis in intensive care units in Turkey: a multicenter, point-prevalence study. Crit Care. 2018 Apr 16;22(1):93. doi: 10.1186/s13054-018-2013-1.

Study record dates

Study Major Dates

• Study Start (Actual): January 27, 2016
• Primary Completion (Actual): January 28, 2016
• Study Completion (Actual): February 27, 2016

Study Registration Dates

• First Submitted: August 9, 2017
• First Submitted That Met QC Criteria: August 11, 2017
• First Posted (Actual): August 15, 2017

Study Record Updates

• Last Update Posted (Actual): August 15, 2017
• Last Update Submitted That Met QC Criteria: August 11, 2017
• Last Verified: August 1, 2017

More Information

Terms related to this study

• Keywords: ICU; Sepsis; Point prevalence
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Systemic Inflammatory Response Syndrome; Inflammation; Sepsis; Toxemia
• Other Study ID Numbers: TurkishICS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No